GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31

GENELUX Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$2.45+0.03 (+1.24%)

Close on Oct 19, 2026

Market cap: $110.15M
P/E (TTM): –
Dividend yield: –

GENELUX Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	0.01	0.01	0.17	11
Research & Development	20	19	13	9.08
General & Administrative	13	13	12	5.00
Operating Expenses	33	32	24	14
Operating Income	-33	-32	-24	-3.01
Interest Expense	–	–	0.17	–
Interest & Investment Income	0.71	0.70	0.18	–
Other Non-Operating Income	1.07	1.83	-4.13	-1.09
Income Tax Expense	–	–	–	1.10
Net Income	-32	-30	-28	-5.21
EPS (Basic)(per share)	-0.86	-0.95	-1.16	-0.57
EPS (Diluted)(per share)	-0.86	-0.95	-1.16	-0.57
Shares Outstanding (Basic, Weighted)(shares)	37	31	31	9.12
Shares Outstanding (Diluted, Weighted)(shares)	37	31	24	9.12

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -455275.0%
Net margin: -444950.0%
Return on equity, FY2025: -170.0%

Financial strength

Current ratio: 2.39
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 114.8%

Valuation

P/E ratio: –
Price to sales: 13768.82
Price to book: 6.84
Dividend yield: –